A few days ago, Hurun Research Institute released the 2023 Hurun Global Future Unicorn: Global Gazelle Enterprise List and the 2023 Hurun Global Gazelle Investment Institution TOP50 List. The Hurun Global Future Unicorn List lists global gazelle companies, that is, high-growth companies that were founded after 2000 and are most likely to reach unicorn-level billion-dollar valuations within three years; The current valuation of the gazelle companies on the list is generally between $500 million and $1 billion. The deadline for calculating the valuation of this list is December 31, 2022. The Hurun Global Gazelle Investment Institutions TOP50 List lists the world's most successful gazelle investment institutions based on the number of institutional investment companies, including venture capital institutions (VCs), private equity institutions (PE) and corporate venture capital institutions (CVCs).
Qiming Venture Capital was named China's most successful gazelle investment institution TOP5 with nearly 30 companies on the list, and ranked 10th in the 2023 Hurun Global Gazelle Investment Institution TOP50. These companies include: AiXin Yuanzhi, Qiniu Cloud, Boliu Intelligence, Mecamand Robot, XSKY Star Trinax, Shiftcore Communication, Yunji Technology, Lisheng Electronics, Ground Railway, 52TOYS, NEIWAI Inside and Outside, Svideng, PETKIT Xiaopei, Aikebaifa, Banger Orthopedics, Beixin Life Sciences, Boossis, Chentai Pharmaceutical, Dingtai Pharmaceutical Research Group, Guanke Meibo, Herui Gene, Hengyi Biotechnology, Jingyu Medical, Connostern, Mace Health, Norcon, Insil Intelligence, Yuanbao, Zhenge Biotechnology.
Qiming Ventures
Awarded
China's most successful gazelle investment institution TOP5
Top 10 global gazelle investment institutions
AiXin Yuanzhi, Qiniu Cloud, Boliu Intelligence
Mecamand robot, XSKY Star TRW
Core shift communication, Yunji technology, Hunt Electronics
Inside and outside the Ground Railway, 52TOYS, NEIWAI
SVIDEN, PETKIT PETKIT, IKOBAFA
Banger Orthopedics, Beixin Life Sciences, Booses
Chentai Pharmaceutical, Dingtai Pharmaceutical Research Group, Crown Beauty Bo
Herui Gene, Hengyi Biotechnology, Jingyu Medical
Connosten, Mace Health, Norcon
Insilico, Yuanbao, Zhenge Biotechnology
Honored
Hurun Global Future Unicorn: Global Gazelle Enterprise List
This is the third time that the Hurun Research Institute has released this list.
01/
Global Gazelle Enterprise List
The Hurun Research Institute found 688 gazelle companies worldwide, up 163 from 525 a year ago. The United States and China lead with 247 and 218 gazelle companies, respectively, accounting for 68% of the global gazelle total. In terms of cities, San Francisco and Shanghai are the gazelle capitals of the world, with 67 and 63 respectively, followed by Beijing and New York. There are 102 gazelle enterprises in China's Yangtze River Delta region, an increase of 15 from 87 a year ago, accounting for 47% of the country; There are 48 in the Guangdong-Hong Kong-Macao Greater Bay Area, an increase of 17 from 31 a year ago, accounting for 22% of the country.
The main industries for global gazelle companies are fintech, biotech and software services, followed by health technology, e-commerce and artificial intelligence. 74% sell software and services, and only 26% sell physical products. 57% are enterprise-oriented and 43% consumer-facing. Average was established in 2015.
02/
Hurun commented on the gazelle
Hu Run, Chairman and Chief Research Officer of Hurun Report, said: "Hurun Global Future Unicorns: Global Gazelle Enterprises lists the startups in the world that are most likely to 'become unicorns' within three years. The gazelle represents the economy of the future. What they're doing and where they're doing it shows which industries attract the world's top young talent and brightest capital. ”
"Hurun Global Future Unicorns: The compilation of the Global Gazelle Enterprise List refers to the information provided by many of the world's top investment institutions, which may be the world's most comprehensive list of future unicorns."
"The future of Hurun Global Gazelle Enterprises is a global unicorn, with 89 (18%) of the 508 new unicorns in the world coming from last year's Hurun Global Gazelle Enterprises. Among this year's new unicorns, another 2% are from Hurun Global Future Unicorn: Global Cheetah Enterprises, which means that in the two Hurun Future Unicorn lists, we have identified 20% of the new unicorns in the world this year. In China, we have successfully identified 40% of the 107 new unicorns in the gazelle and cheetah list. ”
"The role of investment institutions is shifting from merely providing funding to mentoring and scaling opportunities. The world's leading gazelle investors are building ecosystems with their portfolios, which are attractive to the world's fastest-growing startups. Being able to say that you have one of these brands in your investment institution will significantly increase credibility. ”
Note: Crown Beauty (NASDAQ: APLM) successfully landed on NASDAQ in March 2023, Mace Health (02415. HK) successfully landed on the main board of Hong Kong in April 2023
Source | Hurun Report
Qiming Venture Capital was founded in 2006 and has offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.
At present, Qiming Venture Capital manages 11 USD funds and 7 RMB funds, with a total of US$9.4 billion in assets under management. Since its establishment, it has focused on investing in early and growth stage enterprises in technology and consumer (T&C), healthcare and other industries.
Up to now, Qiming Venture Capital has invested in more than 480 high-growth innovative companies, of which more than 180 are listed on the New York Stock Exchange, NASDAQ, Hong Kong Stock Exchange, Shanghai Stock Exchange and Shenzhen Stock Exchange, and have exited from mergers, and more than 70 companies have become recognized unicorns and super unicorns in the industry.
Many of Qiming's portfolio companies have grown to become the most influential companies in their respective fields, including Xiaomi Group (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Stone Technology (688169.SH), Gan&Lee Pharmaceutical (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), Huitai Medical (688617.SH), Nova Health (06606.HK), Qiming Medical (02500.HK), Sanyou Medical (688085.SH), Adder Biotech (300685.SZ), Berry Gene ( 000710.SZ), Shenzhou Cell (688520.SH), Yuanxin Technology, Kangdia, Faith Medicine, WeRide Zhixing, Bicheng Technology, UBTECH, etc.